Nascent Pharma Holdings (NASC) has a profit margin of -1238.07%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2024
Trailing 12 months ending Sep 2024
The latest profit margin for NASC is -1238.07% as of September 2024. That compares with -442.99% in the prior-year period — down 179.5% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Nascent Pharma Holdings's historical trend and sector peers before judging valuation or financial health.
Over the past year, NASC's profit margin moved from -442.99% to -1238.07% — a 179.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nascent Pharma Holdings's valuation or profitability profile.
Against Healthcare companies, NASC currently prints -1238.07% for profit margin, while the sector average sits near 17.63%. That is roughly 7123.1% below the sector mean. Large gaps often invite a closer look at Nascent Pharma Holdings's growth, margins, and balance sheet.
Profit Margin shows how effectively Nascent Pharma Holdings converts resources into returns. At -1238.07%, NASC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -442.99% in the prior-year period — down 179.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NASC's profit margin (-1238.07%), review year-over-year change from -442.99%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.